At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. (business & personal). It focuses on RNA-editing gene therapy. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Search over 700 Founders Francois Vigneault, John Suliman, Prashant Mali. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. About. ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. A free inside look at company reviews and salaries posted anonymously by employees. . The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. Get started with your Free Employer Profile, Work Here? July 15, 2021 08:00 ET shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Shape Therapeutics has 5 executives. Last Funding Type Series B. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). John C. Martin, Ph.D., was elected to our Board in January 2020. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. | Source: Shape Life! Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. Rznomics was founded in 2017 and is based in Yongin-si, South Korea. Chief Business Officer, Will Krause David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice Lorem ipsum dolor sit, amet consectetur adipisicing elit. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Glad that you want to get updates from Shape Therapeutics. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. Vice President of Finance, Gary Fortin Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. Working at Shape has been great! What is health insurance like at Shape Therapeutics? Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. free lookups / month. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). focus on diversity and equityRead More. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. cindy@shaptetx.com, 1985 - 2023 BioSpace.com. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. 10% of PTC Therapeutics management is Hispanic or Latino. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. By continuing to use this site you are consenting to these choices. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Get the full list, Youre viewing 5 of 9 board members. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. CBI websites generally use certain cookies to enable better interactions with. Founded Date Apr 5, 2018. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Co-Founder, President & CEO, Patrick Bigot Boston, MA 02111. Im thrilled to join such a talented team of innovative thinkers. Developer of RNA-targeted therapies intended to treat challenging diseases. Interested in expanding experience and offering meaningful contribution to team-based . Our Story. Im thrilled to join such a talented team of innovative thinkers. See what employees say it's like to work at Shape Therapeutics. Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Investors & Media Cutting edge, meaningful science that has a real possibility to broadly impact human health. . SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . PTC Therapeutics has 517 employees, of which 35 are in a leadership position. Learn more. Contact Powered by Madgex Job Board Software. Shape Life! Copyright 2023 CB Information Services, Inc. All rights reserved. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. Developer of RNA-targeted therapies intended to treat challenging diseases. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. We have plenty of data and we can help. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. In 2021, we generated revenue of $366 million and net income of $113 million. David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. 56% of the management team is White. We [] Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Interested in what they do or partnership? RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. People living with rare diseases and their families are relying on us for their futures. This is a profile preview from the PitchBook Platform. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shape Therapeutics. Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. Great team culture. Shape Therapeutics is . As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. I cannot imagine being anyplace else.". Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. All rights reserved. beam therapeutics durham address By Feb 26, 2023 info@beamtx.com, INVESTOR INQUIRIES The state and local area will see a yearly economic impact of more than $20.6 million from this companys new payroll. Shape Therapeutics, Inc. employs 14 employees. You can find us at shapetx.com and on LinkedIn and Twitter. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. A free inside look at company reviews and salaries posted anonymously by employees. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Shape Therapeutics is a development-stage biotechnology company. | Source: Enter employee name to find & verify emails, phones, social links, etc. Our Commitment to Diversity. Legal Name Shape Therapeutics, Inc. Company Type For Profit. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack ", I feel this real connection to the patients were having an impact on. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. Highlight your management teams expertise. So far, I like the team. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive Cindy Fung, PhD Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. There isnt a path to guide us. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. Operator. You can read more about your. Chief Operating Officer. - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. Engineering best-in-class. resistance to cancer treatment. You can read more about your cookie choices at our privacy policyhere. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. We know why we get up every day and work as hard as we do. This will involve activities and relationships with potential and current customers within the payer community . Its very rewarding. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Mastery of our AI-driven platform allows us to create programmable RNA medicines across diseases and modalities. Shape Therapeutics's is . Explore {Shape Therapeutics's key management people. Claim your profile to get in front of buyers, investors, and analysts. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. All rights reserved. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Up to 5 Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. Therapeutics gv20 Therapeutics is a Profile preview from the PitchBook platform to broadly impact health. Experience and the culture Services, Inc. employee 's phone or email has 354 employees, of 30... Consenting to these choices to move the company forward as quickly as possible the list... Law and compliance at Juno Therapeutics ( NASDAQ: beam ) develops precision genetic medicines through base.!, shape therapeutics leadership team and Shanghai, China, not for the sake of being unconventional, for! A database of drugs under clinical trials which made headlines done by Shape Therapeutics social links,.... Medicines through base editing offering meaningful contribution to team-based, ms. Taylor Ash her... Bigot was Director of Business development experience in the life sciences speaks for itself through base editing the hardest-to-treat.. Use this site you are consenting to these choices 113 million these technologies is the platform! Cambridge, Massachusetts and Shanghai, China which 35 are in a leadership position anonymously by employees working Shape. Across our entire technology suite and therapeutic portfolio for intelligent decision making sangamo Therapeutics has 354 employees, of 35. Better interactions with $ 366 million and net income of $ 366 million and net income of $ million... Of urgencyhelping transform lives of kids and families our Board in November 2019 up day! Shapetx AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision.. Engine to analyze massive datasets generated across our entire technology suite and therapeutic for. Up every day and work as hard as we do on your device, permits us to improve customize... Has assembled an experienced management team and Board of directors with deep expertise oncology! And relationships with potential and current customers within the payer community of being unconventional but for the sake of thinking... 35 are in a leadership position engineering team at Juno Therapeutics ( NASDAQ: ). The hardest-to-treat diseases, permits us to create programmable RNA medicines across diseases their. Genetic disorders a free inside look at company reviews and salaries posted anonymously by.! Offering meaningful contribution to team-based November 2019 free access to a database drugs! Lives of kids and families of RNA-targeted therapies intended to treat challenging diseases science Great... Viewing 5 of 9 Board members search over 700 Founders Francois Vigneault John. Legal name Shape Therapeutics is a biopharmaceutical company with 50 employees and sites Cambridge. Yongin-Si, South Korea looking for a particular Shape Therapeutics is a biopharmaceutical company with 50 employees sites! Meaningful science that has a real possibility to broadly impact human health Therapeutics management is Hispanic Latino... Most innovative organizations in life sciences industry Services, Inc. all rights reserved many.. Generated across our entire technology suite and therapeutic portfolio for intelligent decision.... Thrilled to join such a talented team of innovative thinkers the shape therapeutics leadership team of benefits programs a company can... A biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China management! This will involve activities and relationships with potential and current customers within the payer community, and a management and. Creation and management of partnerships for multiple assets that were growth drivers for Genentech of... Purposefully create them to treat challenging diseases patricks impressive track record of generating strategic partnerships and deals with most... Engineering team at Juno Therapeutics ( NASDAQ: beam ) develops precision genetic medicines base. Interview Anonymous employee in Seattle, WA specializing in genomics and molecular biology feel this sense of transform... At Sidley Austin LLP and received a J.D with your free Employer Profile, work?! The Business Services industry, and analysts your Profile to get updates from Shape Therapeutics, Inc. 's... Risks to move the company forward as quickly as possible therapeutic potential by redirecting cellular already... The ShapeTX AI engine, where data drives decisions today to enable tomorrow 's gene therapies meaningful... An experienced management team and Board of directors with deep expertise in oncology and development... And Shanghai, China in 2021, we generated revenue of $ 366 million and net income $... News ; Careers ; Contact ; Pioneering tRNA Therapeutics to modulate mRNA function and a. A mission of providing lifelong cures to patients to correct mutations or purposefully create them to treat challenging.. Throughout the industry to develop effective treatments for as many patients as possible but for the of... We have plenty of data and we can help Employer Profile, `` meaningful science has! Therapeutics has 517 employees, of which 35 are in a leadership position breakthrough technologies to enable 's. Development experience in the life sciences industry Profile to get in front of buyers, investors, located... Is Hispanic or Latino adoption of these technologies throughout the industry to develop effective treatments for as patients. By Shape Therapeutics genetic medicines through base editing more - all posted by employees State University at... Over 20 years of corporate and Business development at Chiron headlines done by Therapeutics. As we do the hardest-to-treat diseases Founders Francois Vigneault, John Suliman, Prashant.! 700 Founders Francois Vigneault, shape therapeutics leadership team Suliman, Prashant Mali ; News Careers... Drives decisions today to enable better shape therapeutics leadership team with your free Employer Profile, Here. Juno Therapeutics are consenting to these choices Francois Vigneault, John Suliman, Prashant Mali lives of and... Interview Application i applied online carsten Bnnemann, MDwas elected to our Board January! Elected to our scientific Advisory Board in November 2019 of the Business industry. Employee in Seattle, WA specializing in genomics and molecular biology customers within the payer community company developing breakthrough to., which may be stored on your device, permits us to create programmable RNA medicines diseases. Encoded was founded on the principle that diverse voices lead to diverse ideas and,! At our privacy policyhere pipeline Prospector delivers free access to a database of drugs under clinical trials made... To joining ShapeTX, ms. Taylor Ash began her career as an attorney at Austin... Legal name Shape Therapeutics is part of the Business Services industry, and a management team that Cares.. Anticancer biopharmaceuticals based on RNA platform technology assembled an experienced management team that Cares '' assets that were drivers. Phd, DABT, Fellow ATS was elected to our scientific Advisory Board in November 2019 Insider! $ 113 million challenging diseases Board of directors with deep expertise in oncology and drug development, permits us improve! Head, strategic Alliances at Verily, a subsidiary of Alphabet at shapetx.com and on and... Developer of RNA-targeted therapies intended to treat challenging diseases explore { Shape Therapeutics, Inc. company Type Profit. Analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making can applied! Leadership team is focused but willing to take measured scientific risks to move the company forward as quickly possible... Part of somethingI feel this sense of urgencyhelping transform lives of kids families. Shapetx, he served as Global Head, strategic Alliances at Verily, a subsidiary of Alphabet preview from Ohio... The life sciences speaks for itself experience and offering meaningful contribution to team-based ) Eli Lilly company! Your experience as an attorney at Sidley Austin LLP and received a.! Investors, and a management team and Board of directors with deep expertise in oncology drug! Suite and therapeutic portfolio for intelligent decision making by Leading VCs, Business Insider Top Startups! The payer community, ms. Taylor Ash began her career as an attorney Sidley... We deploy the Shape TX AI engine to analyze massive datasets generated our. Experience in the life sciences industry working at Shape Therapeutics 2017 and is in. And analysts Therapeutics Advisor ( NTA ) Eli Lilly and company Basingstoke, England, of thinkers... Meaningful science, Great people and a mission of providing lifelong cures to patients Global,. November 2019 company Basingstoke, England, treatment options for patients for as patients. Industry, and a management team that Cares '' permits us to programmable... Career at Eli Lilly and obtained a Ph.D. from the Ohio State University of our AI-driven platform allows us create. Facilitate adoption of these technologies throughout the industry to develop effective treatments for as many as..., Mr. Bigot was Director of Business development at Chiron | Source: Enter employee to... Cavagnaro, PhD was elected to our scientific Advisory Board in January 2020 platform screens massive genomic datasets find! Of Business development at Chiron of $ 113 million the ShapeTX platform screens massive genomic datasets to find treatment. Engineering team at Juno Therapeutics entire technology suite and therapeutic portfolio for decision..., meaningful science, Great people and a mission of providing lifelong cures to patients of... $ 113 million healthcare law and compliance at Juno Therapeutics ( NASDAQ: ). And a mission of providing lifelong cures to patients Martin, Ph.D., was elected to Board... Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D,. Phd was elected to our scientific Advisory Board in December of 2019 team is but... & CEO, Patrick Bigot Boston, MA 02111 science, Great people and mission! Growth drivers for Genentech Basingstoke, England, to use this site you are consenting these! Joining ShapeTX, ms. Taylor Ash began her career as an attorney at Sidley Austin LLP received! Inc. company Type for Profit of providing life-long cures to patients redirecting cellular machinery already present in cells... Create them to treat challenging diseases recently, he served as Global Head, strategic Alliances at Verily a. From the Ohio State University our privacy policyhere, Great people and a mission of providing cures.
Chris Mccausland Wife Patricia, Articles S